MedTrace Logo

Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

NCT01153360 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-07-24

No results posted yet for this study

Summary

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Conditions

  • Non-thyroidal Illness Syndrome

Interventions

DRUG

liothyronine sodium

liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)

DRUG

placebo

vitamin B12

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Yong-Sun Choi, MD, Ph.D · Anesthesiology & Pain Medicine, Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153360 on ClinicalTrials.gov